Krsnaa Diagnostics is Live on SOPHiA GENETICS
April 11 2023 - 9:00AM
Business Wire
SOPHiA DDM™ for Hereditary Cancers Enables
Krsnaa Diagnostics to Expand its NGS Offerings
SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company
in the healthcare space and a leader in data-driven medicine, today
announced that Krsnaa Diagnostics, India’s largest diagnostic
services provider in radiology and pathology, is live on SOPHiA
DDM™ technology. Krsnaa Diagnostics is using the SOPHiA DDM™ for
Hereditary Cancers Solution to expand their current next-generation
sequencing (NGS) offerings.
Hereditary causes account for approximately 10 percent of cancer
cases1 and identification of individuals with suspected hereditable
cancer can lead to preventative examinations and additional
discussions with their physicians. Next-generation sequencing (NGS)
is transforming the way genomic evaluation of hereditary cancers is
performed and integrated into the daily workflow of clinical and
research laboratories around the world. SOPHiA DDM™ for Hereditary
Cancers Solution enables Krsnaa to provide high-quality NGS tests
that help to evaluate for hereditary cancers.
Krsnaa works to be accessible and affordable to anyone who seeks
a high-quality NGS test. With SOPHiA GENETICS technology Krsnaa
will advance its NGS offerings and help to democratize data-driven
medicine.
“At SOPHiA GENETICS we pride ourselves on collaborating with
cutting-edge laboratories and research institutions and working
with them to bring data-driven medicine closer to all,” said Ken
Freedman, Chief Revenue Officer, SOPHiA GENETICS. “Krsnaa is
working to make precision medicine a reality for everyone in India
and we are honored to support their work by offering our Hereditary
Cancer Solution to expand their NGS offerings.”
The use of next-generation sequencing (NGS) aids significantly
in detecting biomarkers for hereditary cancers but also provides a
vast and complex dataset for analysis. The SOPHiA DDM™ for
Hereditary Cancers Solution uses artificial intelligence and
machine learning with patented technologies to analyze raw NGS
data, making it faster and easier for experts to analyze and
interpret findings from NGS data with confidence.
For more information on SOPHiA GENETICS, visit
SOPHiAGENETICS.COM, or connect on Twitter, LinkedIn,
Facebook, and Instagram.
About SOPHiA GENETICS SOPHiA GENETICS (Nasdaq: SOPH) is a
cloud-native software company in the healthcare space dedicated to
establishing the practice of data-driven medicine as the standard
of care and for life sciences research. It is the creator of the
SOPHiA DDM™ Platform, a cloud-native platform capable of analyzing
data and generating insights from complex multimodal data sets and
different diagnostic modalities. The SOPHiA DDM™ Platform and
related solutions, products and services are currently used by a
broad global network of hospitals, academic centers, laboratories
and biopharma institutions. For more information, visit
SOPHiAGENETICS.COM, or connect on Twitter, LinkedIn,
Facebook, and Instagram. Where others see data, we see
answers.
SOPHiA GENETICS products are for Research Use Only and not for
use in diagnostic procedures unless specified otherwise. The
information in this press release is about products that may or may
not be available in different countries and, if applicable, may or
may not have received approval or market clearance by a
governmental regulatory body for different indications for use.
Please contact support@sophiagenetics.com to obtain the appropriate
product information for your country of residence.
SOPHiA GENETICS Forward-Looking Statements: This press
release contains statements that constitute forward-looking
statements. All statements other than statements of historical
facts contained in this press release, including statements
regarding our future results of operations and financial position,
business strategy, products, and technology, as well as plans and
objectives of management for future operations, are forward-looking
statements. Forward-looking statements are based on our
management’s beliefs and assumptions and on information currently
available to our management. Such statements are subject to risks
and uncertainties, and actual results may differ materially from
those expressed or implied in the forward-looking statements due to
various factors, including those described in our filings with the
U.S. Securities and Exchange Commission. No assurance can be given
that such future results will be achieved. Such forward-looking
statements contained in this press release speak only as of the
date hereof. We expressly disclaim any obligation or undertaking to
update these forward-looking statements contained in this press
release to reflect any change in our expectations or any change in
events, conditions, or circumstances on which such statements are
based, unless required to do so by applicable law. No
representations or warranties (expressed or implied) are made about
the accuracy of any such forward-looking statements.
1 Al Harthi, F. S., et al. (2020) ‘Familial/inherited cancer
syndrome: a focus on the highly consanguineous Arab population’,
npj Genomic Medicine, 5, 3
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230411005330/en/
Media: Nick Puleo npuleo@comsint.com
Sophia Genetics (NASDAQ:SOPH)
Historical Stock Chart
From May 2024 to Jun 2024
Sophia Genetics (NASDAQ:SOPH)
Historical Stock Chart
From Jun 2023 to Jun 2024